Abstracts tagged "Lupus nephritis"

Abstract Number: 0640 • ACR Convergence 2022
Immune Cell Heterogeneity in Lupus Nephritis Kidneys and Its Relation to Histopathological Features
Arnon Arazi¹, Joseph Mears², Thomas Eisenhaure³, Qian Xiao⁴, Paul Hoover⁴, Deepak Rao⁴, Celine Berthier⁵, Andrea Fava⁶, Siddarth Gurajala⁴, Michael Peters³, Tony Jones³, William Apruzzese⁴, Jennifer Barnas⁷, Richard Furie⁸, Anne Davidson⁹, David Hildeman¹⁰, Judith James¹¹, Joel Guthridge¹¹, Maria Dall'Era¹², David Wofsy¹³, Peter Izmirly¹⁴, H Michael Belmont¹⁵, Robert Clancy¹⁴, Diane Kamen¹⁶, Chaim Putterman¹⁷, Thomas Tuschl¹⁸, Maureen McMahon¹⁹, Jennifer Grossman¹⁹, Kenneth Kalunian²⁰, Michael Weisman²¹, Matthias Kretzler⁵, Michael Brenner²², Jennifer Anolik²³, Michelle Petri²⁴, Jill Buyon¹⁴, Soumya Raychaudhuri⁴, Nir Hacohen³, Betty Diamond⁹ and the Accelerating Medicines Partnership RA/SLE Network³, ¹Feinstein Institutes for Medical Research, Melrose, MA, ²Michigan University, Ann Arbor, MI, ³Broad Institute, Cambridge, MA, ⁴Brigham and Women's Hospital, Boston, MA, ⁵University of Michigan, Ann Arbor, MI, ⁶Johns Hopkins University, Baltimore, MD, ⁷University of Rochester, Rochester, NY, ⁸Northwell Health, Great Neck, NY, ⁹Feinstein Institutes for Medical Research, Manhasset, NY, ¹⁰Cincinnati Children's Hospital, Cincinnati, OH, ¹¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹²University of California, Division of Rheumatology, San Francisco, CA, ¹³University of California San Francisco, SF, CA, ¹⁴NYU Grossman School of Medicine, New York, NY, ¹⁵NYU School of Medicine, New York, NY, ¹⁶Medical University of South Carolina, Charleston, SC, ¹⁷Albert Einstein College of Medicine, Bronx, NY, ¹⁸Rockefeller University, New York, NY, ¹⁹University of California Los Angeles, Los Angeles, CA, ²⁰University of California San Diego, La Jolla, CA, ²¹Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, Los Angeles, CA, ²²Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²³University of Rochester Medical Center, Rochester, NY, ²⁴Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD
Background/Purpose: Lupus nephritis (LN) is characterized by considerable variability in its clinical manifestations and histopathological findings. Understanding the cellular and molecular mechanisms underlying this heterogeneity…
Abstract Number: 1334 • ACR Convergence 2022
Exploring Canadian Patient Experiences of Living with Lupus Nephritis (LN)
Francesca S Cardwell¹, Sydney George², Adrian Boucher², Megan R W Barber³, Kim Cheema⁴, Susan J Elliott⁵ and Ann E Clarke³, ¹University of Waterloo, Department of Geography & Environmental Management, Burlington, ON, Canada, ²GlaxoSmithKline, Health Outcomes and Economics, Mississauga, ON, Canada, ³University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada, ⁴University of Calgary, Division of Nephrology, Cumming School of Medicine, Calgary, AB, Canada, ⁵University of Waterloo, Department of Geography & Environmental Management, Waterloo, ON, Canada
Background/Purpose: LN is one of the most severe manifestations of SLE; however, the patient experience remains understudied. This research investigates patient experiences and perspectives of…
Abstract Number: 1694 • ACR Convergence 2022
Skin Exposure to UV Light Triggers Podocyte and Distal Tubular Injury, in the Presence of CD177+ Neutrophil Cell Cluster
Angelique Cortez¹, Lindsay Mendyka¹, Fred Kolling² and Sladjana Skopelja-Gardner¹, ¹Dartmouth Hitchcock Medical Center, Lebanon, NH, ²Geisel School of Medicine at Dartmouth, Lebanon, NH
Background/Purpose: Sensitivity to ultraviolet (UV) light affects ~ 80% of systemic lupus erythematosus (SLE) patients. UV light exposure of lupus skin leads to local and…
Abstract Number: 2099 • ACR Convergence 2022
Drug Repurposing for Treating Lupus Nephritis Based on Transcriptome Profiling and Autoimmunity-Related Serological Markers
Ioannis Parodis¹, Julius Lindblom¹, Daniel Toro-Domínguez², Elena Carnero-Montoro², Maria Orietta Borghi³, Jessica Castillo⁴, Yvonne Enman⁵, Chandra Mohan⁴, Marta Alarcon-Riquelme² and Guillermo Barturen², ¹Karolinska Institutet, Stockholm, Sweden, ²Center for Genomics and Oncological Research (GENYO), Granada, Spain, ³Università degli Studi di Milano and Istituto Auxologico Italiano, Milano, Italy, ⁴University of Houston, Houston, TX, ⁵Karolinska Institutet, Sundbyberg, Sweden
Background/Purpose: LN is one of the most severe organ manifestations of SLE and constitutes an important cause of morbidity and death among patients with SLE…
Abstract Number: 0355 • ACR Convergence 2022
Long-term Use of Voclosporin in Patients with Class V Lupus Nephritis: Results from the AURORA 2 Continuation Study
Amit Saxena¹, Dawn Caster², Salem Almaani³, Amber Rosales⁴ and Henry Leher⁵, ¹NYU School of Medicine, New York, NY, ²University of Louisville, Louisville, KY, ³The Ohio State University Medical Center, Columbus, OH, ⁴Aurinia Pharmaceuticals Inc., Rockville, MD, ⁵Aurinia Pharmaceuticals Inc, Rockville, MD
Background/Purpose: Persistent proteinuria increases the risk of comorbidities in lupus nephritis, and rapid reductions in protein have shown to be predictive of improved long-term renal…
Abstract Number: 0647 • ACR Convergence 2022
Transcriptomic Analysis of Lupus Nephritis Kidneys Identifies Molecular Endotypes
Kathryn Kingsmore Allison¹, Sneha Shrotri¹, Prathyusha Bachali², Nan Shen³, Amrie Grammer⁴ and Peter Lipsky¹, ¹AMPEL BioSolutions, Charlottesville, VA, ²AMPEL BioSolutions, Redmond, WA, ³Shanghai Jiang Tong University School of Medicine, Shanghai, China, ⁴AMPEL LLC, Charlottesville, VA
Background/Purpose: Predicting the course or response to treatment of lupus nephritis (LN) from standard renal biopsies is problematic. We, therefore sought to understand the molecular…
Abstract Number: 1347 • ACR Convergence 2022
Poor Health-Related Quality of Life in Patients with Lupus Nephritis
Cristina Arriens¹, Janice Ma², Konrad Pisarczyk², Richard Leff³, Kiruthi Palaniswamy⁴ and Li Long⁴, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Maple Health Group, LLC, New York, NY, ³Kezar Life Sciences, South San Francisco, CA, ⁴Kezar Life Sciences, Inc., South San Francisco, CA
Background/Purpose: Lupus nephritis (LN) is one of the most serious manifestations of systemic lupus erythematosus (SLE) associated with considerable morbidity that has a devastating impact…
Abstract Number: 1697 • ACR Convergence 2022
Measurements of Specific Activation Through the Lectin -or Classical Pathway of Complement in Patients with SLE
Anne Troldborg¹, Mads Lamm Larsen¹, Erik J.M. Toonen², Lisa Hurler³, Zoltan Prohaszka³, László Cervenak³, Annette Gudmann Hansen⁴ and Steffen Thiel⁴, ¹Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ²Hycult Biotech, Arnhem-Nijmegen, Netherlands, ³Semmelweis University, Budapest, Hungary, ⁴Aarhus University, Aarhus, Denmark
Background/Purpose: In systemic lupus erythematosus (SLE), the complement system is activated and commonly thought to occur through the classical pathway (CP) [1]. However, our previous…
Abstract Number: 2222 • ACR Convergence 2022
Lupus Clinical Flares in Patients with Gut Pathobiont Blooms Share a Novel Peripheral Blood Transcriptomic Immune Activation Profile
Gregg Silverman¹, Macintosh Cornwell¹, Peter Izmirly¹, Mala Masson¹, Jill Buyon¹, Doua Azzouz² and Kelly Ruggles¹, ¹NYU Grossman School of Medicine, New York, NY, ²NYU Gross School of Medicine, New York, NY
Background/Purpose: SLE is an inflammatory condition associated with hyperactivation of the immune system, with mounting evidence that imbalances in the gut microbiota communities are common.…
Abstract Number: 0356 • ACR Convergence 2022
Early Reductions in Proteinuria with Voclosporin Treatment Across Lupus Nephritis Biopsy Classes: Pooled Data from the AURA-LV and AURORA 1 Trials
Anca Askanase¹, Lucy Hodge², Vanessa Birardi³ and Henry Leher³, ¹Columbia University Medical Center, New York, NY, ²Aurinia Pharmaceuticals, Seattle, WA, ³Aurinia Pharmaceuticals Inc, Rockville, MD
Background/Purpose: Voclosporin, a novel calcineurin inhibitor, is approved for the treatment of adults with lupus nephritis in combination with background immunotherapy and was successfully tested…
Abstract Number: 0648 • ACR Convergence 2022
Pathogenic Anti-C1q Antibodies Potentiate Activation of the Classical Complement Pathway in a Subset of Lupus Nephritis Patients
Edmund Chang¹, Julian Low², Ellen Cahir-McFarland², Henk-Andre Kroon², Yaisa Andrews-Zwilling², Ted Yednock² and Ann Mongan², ¹Annexon Biosciences, Brisbane, CA, ²Annexon Biosciences, South San Francisco, CA
Background/Purpose: In LN, excess immune complexes lead to nephrotic deposition of C1q and C4d, the latter of which has been correlated with circulating C4d and…
Abstract Number: 1360 • ACR Convergence 2022
Clinical Characteristics and Outcomes of North American Youth with Lupus Nephritis Requiring Dialysis Treated with Cyclophosphamide
Christine Wang¹, Rebecca Sadun², Wenru Zhou³, Kristen Miller³, Claire Palmer³, Stacy P Ardoin⁴, Christine Bacha⁵, Emily Hause⁶, Joyce Hui-Yuen⁷, Nicole Ling⁸, Maria Pereira⁹, Meredith Riebschleger¹⁰, Kelly Rouster-Stevens¹¹, Aliese Sarkissian¹², Julia Shalen¹³, William Soulsby¹⁴, Marinka Twilt¹⁵, Eveline Wu¹⁶, Laura Lewandowski¹⁷, Scott Wenderfer¹⁸ and Jennifer Cooper¹⁹, ¹Children's Hospital of Colorado/University of Colorado, Denver, CO, ²Duke University, Durham, NC, ³University of Colorado School of Medicine, Aurora, CO, ⁴Division of Rheumatology, Nationwide Children's Hospital and Department of Pediatrics, The Ohio State University, Columbus, OH, ⁵Nationwide Children's Hospital, Columbus, OH, ⁶University of Minnesota, Minneapolis, MN, ⁷Cohen Children’s Medical Center, Hofstra-Northwell School of Medicine, Feinstein Institutes for Medical Research, Queens, NY, ⁸UCSF, San Francisco, CA, ⁹Baylor College of Medicine, Houston, TX, ¹⁰University of Michigan, Ann Arbor, MI, ¹¹Emory University/Children's Healthcare of Atlanta, Atlanta, GA, ¹²University of North Carolina at Chapel Hill, Chapel Hill, NC, ¹³Johns Hopkins University, Baltimore, MD, ¹⁴University of California, San Francisco, San Francisco, CA, ¹⁵Alberta Children's Hospital, Calgary, AB, Canada, ¹⁶University of North Carolina, Chapel Hill, NC, ¹⁷NIAMS, NIH, Bethesda, MD, ¹⁸British Columbia Children's Hospital, Vancouver, BC, Canada, ¹⁹University of Colorado/Children's Hospital Colorado, Denver, CO
Background/Purpose: Few studies have evaluated the clinical characteristics and outcomes of youth with lupus nephritis (LN) treated with cyclophosphamide (CYC) who initially required kidney replacement…
Abstract Number: 1716 • ACR Convergence 2022
The Transcriptomic Landscape of Nephritic Kidneys Reveals Mechanisms for End Organ Resistance to Damage in Lupus-prone Mice
Andrea Daamen¹, Hongyang Wang², Prathyusha Bachali³, Shu Man Fu², Amrie Grammer⁴ and Peter Lipsky¹, ¹AMPEL BioSolutions, Charlottesville, VA, ²University of Virginia, Charlottesville, VA, ³AMPEL BioSolutions, Redmond, WA, ⁴AMPEL LLC, Charlottesville, VA
Background/Purpose: Pathologic inflammation is a major driver of kidney damage in lupus nephritis (LN), but the immune mechanisms of disease progression and risk factors for…
Abstract Number: PP13 • ACR Convergence 2022
How Becoming Engaged in My Care with Specialized Tools and Support Helped Me Find My Personal Lupus Triggers and Regain Control of My Health
Tonya Hinton-Green, Philadelphia, PA
Background/Purpose: My story begins in the ER where I was diagnosed with lupus right after my 22nd birthday.For the next 25 years I went from…
Abstract Number: 0059 • ACR Convergence 2022
Healthcare Resource Utilization and Costs of Management of Lupus Nephritis in Adult and Juvenile Patients with Systemic Lupus Erythematosus
Kenneth Kalunian¹, Janice Ma², Konrad Pisarczyk², Richard Leff³, Kiruthi Palaniswamy⁴ and Li Long⁴, ¹University of California San Diego, La Jolla, CA, ²Maple Health Group, LLC, New York, NY, ³Kezar Life Sciences, South San Francisco, CA, ⁴Kezar Life Sciences, Inc., South San Francisco, CA
Background/Purpose: Lupus nephritis (LN) is one of the most serious complications of systemic lupus erythematosus (SLE), which develops in about one-third of SLE patients within…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].